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Abstract 
Background: Hepatitis B virus (HBV) still continues to infect many people worldwide despite the availability 
of an effective vaccine for more than three decades. The high prevalence of HBV may exist in high risk groups, 
particularly among intravenous drug users (IDUs). This group is among groups with a higher risk of infection 
due to their hazardous behaviors such as sharing needles for drug injection. This cross sectional study included 
229 intravenous drug users in Tehran, in 2013 to investigate the prevalence of HBc Ab positivity and its 
associated risk factors among IDUs. 
Materials and Methods: Socio-demographic characteristics and associated risk factors were recorded during 
sample collection. Their serum samples were tested for the presence of total hepatitis B virus core antibody 
(HBc Ab) by Enzyme-linked Immunosorbent Assay (ELISA). 
Results: HBc Ab was detected in 64 of 229 participants, giving an overall prevalence of 28%. History of 
imprisonment, injecting drugs and age has a significant correlation with HBc Ab positivity. 
Conclusion: Expansion of new preventive strategies through the national health system could be beneficial for 
decreasing the risk of acquiring HBV among high risk groups such as IDUs. 
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Introduction 
The risk of acquiring blood-borne infectious diseases 
are particularly high among intravenous drug users 
(IDUs). Hazardous behaviors of these addicts such as 
sharing syringes, using the same syringe several 
times, or using infected syringes are the main routes 
to be infected with HIV, Hepatitis B, and C viruses 
and various lung and cerebral abscesses
1
. There is a 
direct relationship between the level of cases infected 
by these viruses and duration of injection drug use
2
. 
The greater likelihood of transmission can occur by a 
longer duration of drug use that may lead to more 
sharing of needles and other equipment. It has been 
reported in other studies that being in prison for a 
long time and having a drug injection behavior are 
independently associated with HBV infection
3
. 
According to reports of the Iranian Welfare 
Organization, there are 1.8 million drug users in Iran 
and 9 to 16 percent of them are IDUs. It is interesting 
to note that half of them shared needles. It could be 
estimated that the IDU population in Iran ranges 
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between 200000 and 300000 IDUs. The increasing 
number of intravenous drug users in Iran could be a 
potential danger to the national health system
4
. 
Injection drug usage has been the most growing route 
of drug abuse in Iran in the past decade
5
. The high 
rates of HCV and HBV infection among IDUs have 
been reported in Iran
3,6,7
. This study examined the 
characteristics, risk behaviors and risk factors 
associated with the prevalence of hepatitis B virus 
core antibody (HBc Ab) among IDUs in Tehran. 
Methods 
Sample selection and study population: A cross 
sectional study was conducted on 229 Tehranian 
intravenous drug users in 2013. Details of participant 
selection have been presented in our previous report
8
. 
The study involved face-to-face interviews using 
questionnaires that elicited personal data containing 
demographic data such as age, gender, employment 
status, marital status, the history and duration of 
addiction, the history of imprisonment, the kind and 
route of drug use, hepatitis B vaccination, and some 
high risk behaviors like sharing syringes, sexual 
behaviors, and tattooing. 5ml peripheral blood sample 
was taken from each individual, transported to the 
laboratory, and storage in -20
o
C. IDUs were able to 
receive the results of their tests based on their own 
code number. This study was approved by the ethics 
committee of Shahid Beheshti University of Medical 
Sciences (approval number 6-2015/9/6) and was in 
accordance with the Helsinki Declaration of 1964. 
Detection of serology markers: The serum samples 
were tested for the presence of total HBc Ab by 
Enzyme-linked Immunosorbent Assay (ELISA) with 
commercial kits for HBc Ab detection (Diapro, 
Milan, Italy). The assay is based on the principle of 
competition where the antibodies in the sample 
compete with a monoclonal antibody for a fixed 
amount of antigen on the solid phase. A purified 
recombinant HBc Ag is coated to the microwells. The 
patient’s serum/plasma is added to the microwell 
together with an additive able to block interferences 
present in the sample. In the second incubation after 
washing, a monoclonal antibody, conjugated with 
Horseradish Peroxidase (HRP) and specific for HBc 
Ag is added and binds to the free rec-HBc Ag coated 
on the plate. After incubation, microwells are washed 
to remove any unbound conjugate and then the 
chromogen/substrate is added. In the presence of 
peroxides enzyme the colorless substrate is 
hydrolyzed to a colored end-product. The color 
intensity is inversely proportional to the amount of 
antibodies to HBc Ag present in the sample. 
Statistical analysis: Data were extracted from 
questionnaires and summarized. The standard Chi-
square test was used to assess the correlation of 
demographic and behavioral variables and HBc Ab 
positivity. All analyses were performed using 
statistical package for social sciences (SPSS) software 
version 20. The results were regarded as significant 
when p< 0.05. To avoid interruptions in statistical 
analysis, the injecting drug users who did not answer 
the questions were excluded from the data analysis. 
Results 
HBc Ab was detected in 64 of 229 subjects, giving an 
overall prevalence of 28%. Of 229 IDUs, 17.8% of 
subjects were between 20-30 years old, 37.3% were 
between 30-40 years, 26% were between 40-50, and 
the rest were above 50 years old. Socio-demographic 
profiles of participants, by regarding the number of 
subjects who answered each question, are presented in 
(Table 1).  
Chi-square analysis revealed that there is significant 
association between HBc Ab positivity and injection 
behavior (p= 0.000), history of imprisonment (p= 
0.013) and age of participants (p= 0.012) (Table 2). 
No statistically significant association was observed 
between HBc Ab positivity and sharing needle 
equipment, duration of drug use, frequency of 
injection in a day, type of drug, tattooing, history of 
surgery and high risk sexual behaviors (p>0.05) 
(Table 2). 
Discussion 
In this study, of 229 IDUs, 64 (28%) subjects were 
HBc Ab positive and a significant correlation was 
observed between HBc Ab positivity and injection 
behavior, history of imprisonment, and age of 
participants. Although in our previous study, no  
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Table 1: Socio-demographic characteristics of the studied injecting drug users.  
















Employment status n=173 
  Unemployed 







Marital status n=170 
Married and living with a partner 









Duration of drug usage n=147 
<1 year 
  1-5 years 












History of imprisonment n=162 99 61.1 
Frequency of injection in a day n=84 
  1-3  
  3-6 









History of sharing needle equipment n=82 18 22 
Type of drug n=170 
  Heroin 
  Other*** 









History of tattoo n=159 60 37.7 
History of blood transfusion n=85 24 28.2 
History of surgery n=154 61 39.6 
History of sexual behavior n=99 44 44.4 
History of dentistry n=106 69 65.1 
HBV Vaccination n=129 61 47.3 
*n= number of injection drug user of total 129 cases who answered each question. 
**N= Frequency of each cases 
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Duration of drug use          <1 year 
       1-5 years 
       5-10 years 






















History of imprisonment 
        Yes 















        Yes 













Frequency of injection  
        1-3  














Type of drug 
        Heroin 
        Other* 


















         Yes 














History of surgery 
          Yes 
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High risk sexual behaviors 
           Yes 


















significant relationship was seen between HBs Ag 
positivity and associated risk factors
9
. In a study by 
Merat and colleagues the prevalence HBc Ab in Iran 
was 16.4% in the general population, which was 
lower than our results
10
. In another study on 153 
Iranian injecting drug users by Ramezani and 
colleagues, there was 7.2% HBc Ab prevalence 
among them
11
. Daneshmand et al, study concluded 
that the longer duration of being incarcerated is 
associated with higher prevalence of HBV infection
12
.  
Another descriptive, analytical study on 133 IDUs, 8 
(6.2%) of them were HBV positive, and there was a 
strong correlation between the use of shared needles 
and HBV infection
13
. Also in a conclusion made by 
Nokhodian et al, results for female prisoners in 
Isfahan showed that there was no association between 
the number of arrests and serological HBV markers
14
. 
A study by Nokhodian et al, which was conducted on 
incarcerated intravenous drug users, of 970 
participants 45 (4.64%) were found positive for 
isolated HBc Ab and 67 (6.9%) for both HBs Ab and 
HBc Ab. History of sharing needle showed to have a 
significant association with HBs Ag positivity
15
. 
Another study on females with illegal social 
behaviors in Isfahan, showed the same result that 
demonstrated no association was between having a 
prison history and HBV infection
16
. In Amin-Esmaeili 
et al,study on IDUs, in Tehran, the prevalence of past 
or current HBV infection was high rate (46.1%), that 
was mainly correlated with a history of imprisonment 
and drug use more than 10 years
17
. Some reports from 
Iran
18
 and from other countries regarding 
imprisonment
19,20
 and the frequency
21
 and duration of 
drug injection
19,22
 was demonstrated as risk factors for 
HBV infection. 
Conclusion 
Undoubtedly, IDUs are one of the likeliest groups to 
be exposed to infection and this group would benefit 
from a very high priority in preventive and 
educational programs. Screening and prevention 
programs like modifying behaviors, expanding the 
HBV vaccination coverage, have been instrumental in 
reducing the rate of HBV infection among IDUs. 
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